Loading clinical trials...
Loading clinical trials...
An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder
Conditions
Interventions
sildenafil
Locations
82
United States
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Anchorage, Alaska, United States
Pfizer Investigational Site
Anchorage, Alaska, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Jonesboro, Arkansas, United States
Start Date
January 1, 2003
Completion Date
February 1, 2004
Last Updated
February 1, 2021
NCT05489133
NCT06116045
NCT06651541
NCT05765487
NCT04673708
NCT05093647
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions